Abstract
Investigations were made on clinical use of the new aminoglycosidic antibiotic lividomycin (LVM) in the field of obstetrics and gynecology.
The inhibitory concentrations of the drug for a variety of bacteria isolated from obstetrics and gynecology patients were determined and it was found that LVM has antimicrobial activities nearly identical to, or a little less than kanamycin (KM), against Staphylococcus, E. coli and Klebsiella and that the LVM excels KM to some degree in its antimicrobial activity against Pseudomonas aeruginosa.
Absorption and excretion of LVM proved effective; the maximum serum concentration about 20 mcg/ml was reached within 1 hour after the intramuscular injection of 500 mg and the urinary excretion amounted to approximately 80 within 12 hours. The drug was rated effective in cases of urinary tract infections and pelvic infections when given over about 7 consecutive days with a daily dose of 1.0 g. No side effects were recognized. LVM was judged clinically significant to obstetrical and gynecological infections from all the results described above.
